- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Bausch + Lomb Corp (BLCO)
Bausch + Lomb Corp stock price live, this page displays NYSE BLCO stock exchange data. View the BLCO premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Bausch + Lomb Corp real time stock price chart below.
What Is the Bausch + Lomb Corp Stock Price Today?
The Bausch + Lomb Corp stock price today is 14.46.
What Is the Stock Symbol for Bausch + Lomb Corp?
The stock symbol for Bausch + Lomb Corp is ""BLCO.""
What Stock Exchange Does Bausch + Lomb Corp Trade On?
Bausch + Lomb Corp is listed and trades on the NYSE stock exchange.
Is Bausch + Lomb Corp a Good Stock to Buy?
Determining whether Bausch + Lomb Corp—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the BLCO quote. (ISIN: CA0717051076)
What Is the Bausch + Lomb Corp Stock Price Today?
The Bausch + Lomb Corp stock price today is 14.46.
What Is the Stock Symbol for Bausch + Lomb Corp?
The stock symbol for Bausch + Lomb Corp is ""BLCO.""
What Stock Exchange Does Bausch + Lomb Corp Trade On?
Bausch + Lomb Corp is listed and trades on the NYSE stock exchange.
Is Bausch + Lomb Corp a Good Stock to Buy?
Determining whether Bausch + Lomb Corp—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the BLCO quote. (ISIN: CA0717051076)
Fair Value
An estimate of a Bausch + Lomb's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
14.45
14.65
52 wk Range
10.45
21.69
BLCO Scorecard
Full Analysis
Operates with a significant debt burden
BLCO is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a Bausch + Lomb's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
14.4514.65
52 wk Range
10.4521.69
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
BLCO Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Bausch + Lomb's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Neutral
Price Target
15.14
Upside
+4.72%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Net income is expected to grow this year
- Bausch + Lomb receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- Bausch + Lomb receives Investment Bank Analyst Rating Update
- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Neutral
Moving Averages
Buy
Bausch + Lomb Corp Company Profile
Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lenses that are indicated for therapeutic use and provides optical correction during healing. It also offers contact lens care products, eye vitamins, mineral supplements, and over-the-counter eye drops that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. The Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation operates as a subsidiary of Bausch Health Companies Inc.
Bausch + Lomb Corp SWOT Analysis
Eye Health Pionee | Bausch + Lomb leads in ophthalmology with strong revenue growth, facing challenges and opportunities in a competitive market landscape |
Financial Resilience | Despite foreign exchange headwinds, B+L demonstrates ability to counteract tariffs and projects growth above end markets for 2025 |
Analyst Perspectives | Mixed analyst ratings with price targets ranging from $12 to $22, reflecting varied views on B+L's growth potential and market positioning |
Strategic Focus | Explore B+L's emphasis on Dry Eye Disease portfolio and core segments as key drivers for future growth and market share expansion |
Bausch + Lomb Corp Earnings Call Summary for Q2/2025
- Bausch + Lomb beats Q2 2025 expectations with EPS of $0.07 and revenue of $1.29B, up 3% YoY
- Full-year revenue guidance raised to $5.05-$5.15B, reflecting 5-7% constant currency growth
- Contact lens and dry eye portfolios show significant growth; adjusted gross margin decreased 130 bps YoY
- Stock experienced volatility post-earnings, initially declining 4.91% before recovering slightly in pre-market trading
- CEO emphasizes focus on innovation and market leadership, anticipating full Envista momentum recovery by Q1 2026
Last Updated: 30/07/2025, 15:26
Read Full TranscriptCompare BLCO to Peers and Sector
Metrics to compare | BLCO | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipBLCOPeersSector | |
|---|---|---|---|---|
P/E Ratio | −18.7x | −4.5x | −0.6x | |
PEG Ratio | −0.47 | −0.29 | 0.00 | |
Price/Book | 0.8x | 3.5x | 2.6x | |
Price / LTM Sales | 1.0x | 4.7x | 3.3x | |
Upside (Analyst Target) | 7.2% | 74.8% | 39.1% | |
Fair Value Upside | Unlock | 22.4% | 4.5% | Unlock |
Analyst Ratings
6 Buy
8 Hold
1 Sell
Ratings:
15 analysts
Overall Consensus
Neutral
Analysts 12-Month Price Target:
Average 15.14
(+4.72% Upside)
Earnings
Latest Release
Jul 30, 2025
EPS / Forecast
0.07 / 0.06
Revenue / Forecast
1.29B / 1.26B
People Also Watch
FAQ
What Stock Exchange Does Bausch + Lomb Trade On?
Bausch + Lomb is listed and trades on the New York Stock Exchange stock exchange.
What Is the Stock Symbol for Bausch + Lomb?
The stock symbol for Bausch + Lomb is "BLCO."
What Is the Bausch + Lomb Market Cap?
As of today, Bausch + Lomb market cap is 5.15B.
What Is Bausch + Lomb's Earnings Per Share (TTM)?
The Bausch + Lomb EPS (TTM) is -0.77.
When Is the Next Bausch + Lomb Earnings Date?
Bausch + Lomb will release its next earnings report on 28 Oct 2025.
From a Technical Analysis Perspective, Is BLCO a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Bausch + Lomb Stock Split?
Bausch + Lomb has split 0 times.
How Many Employees Does Bausch + Lomb Have?
Bausch + Lomb has 13500 employees.
What is the current trading status of Bausch + Lomb (BLCO)?
As of 19 Aug 2025, Bausch + Lomb (BLCO) is trading at a price of 14.46, with a previous close of 14.55. The stock has fluctuated within a day range of 14.45 to 14.65, while its 52-week range spans from 10.45 to 21.69.
What Is Bausch + Lomb (BLCO) Price Target According to Analysts?
The average 12-month price target for Bausch + Lomb is USD15.14286, with a high estimate of USD18 and a low estimate of USD12. 6 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Neutral. The stock has an +4.72% Upside potential.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.